JP7334177B2 - 抗ｃｄ７３抗体及びその使用 - Google Patents

抗ｃｄ７３抗体及びその使用 Download PDF

Info

Publication number
JP7334177B2
JP7334177B2 JP2020546997A JP2020546997A JP7334177B2 JP 7334177 B2 JP7334177 B2 JP 7334177B2 JP 2020546997 A JP2020546997 A JP 2020546997A JP 2020546997 A JP2020546997 A JP 2020546997A JP 7334177 B2 JP7334177 B2 JP 7334177B2
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020546997A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019173291A5 (enExample
JP2021516057A (ja
Inventor
ワン，ミンガン
ゾウ，フイ
ペイ，フェン
Original Assignee
フェインズ セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェインズ セラピューティクス，インコーポレーテッド filed Critical フェインズ セラピューティクス，インコーポレーテッド
Publication of JP2021516057A publication Critical patent/JP2021516057A/ja
Publication of JPWO2019173291A5 publication Critical patent/JPWO2019173291A5/ja
Priority to JP2023132024A priority Critical patent/JP7636483B2/ja
Application granted granted Critical
Publication of JP7334177B2 publication Critical patent/JP7334177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fats And Perfumes (AREA)
JP2020546997A 2018-03-09 2019-03-05 抗ｃｄ７３抗体及びその使用 Active JP7334177B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023132024A JP7636483B2 (ja) 2018-03-09 2023-08-14 抗ｃｄ７３抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862640955P 2018-03-09 2018-03-09
US62/640,955 2018-03-09
US201862721044P 2018-08-22 2018-08-22
US62/721,044 2018-08-22
US201862786598P 2018-12-31 2018-12-31
US62/786,598 2018-12-31
PCT/US2019/020688 WO2019173291A1 (en) 2018-03-09 2019-03-05 Anti-cd73 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132024A Division JP7636483B2 (ja) 2018-03-09 2023-08-14 抗ｃｄ７３抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021516057A JP2021516057A (ja) 2021-07-01
JPWO2019173291A5 JPWO2019173291A5 (enExample) 2022-03-10
JP7334177B2 true JP7334177B2 (ja) 2023-08-28

Family

ID=67846304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546997A Active JP7334177B2 (ja) 2018-03-09 2019-03-05 抗ｃｄ７３抗体及びその使用
JP2023132024A Active JP7636483B2 (ja) 2018-03-09 2023-08-14 抗ｃｄ７３抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023132024A Active JP7636483B2 (ja) 2018-03-09 2023-08-14 抗ｃｄ７３抗体及びその使用

Country Status (13)

Country Link
US (1) US11299550B2 (enExample)
EP (1) EP3762030A4 (enExample)
JP (2) JP7334177B2 (enExample)
KR (2) KR102804816B1 (enExample)
CN (2) CN118955714A (enExample)
AU (1) AU2019231172B2 (enExample)
BR (1) BR112020016049A2 (enExample)
CA (1) CA3090008A1 (enExample)
IL (1) IL276950A (enExample)
MX (1) MX2020009366A (enExample)
SG (1) SG11202007199XA (enExample)
WO (1) WO2019173291A1 (enExample)
ZA (1) ZA202004827B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687546A4 (en) 2017-09-26 2022-01-26 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE WITH REDIRECTED T-LYMPHOCYTE IMMUNOTHERAPIES
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
JOP20200342A1 (ar) 2018-07-05 2020-12-30 Incyte Corp مشتقات بيرازين مدمجة كمثبطات a2a/a2b
US12422440B2 (en) 2018-10-05 2025-09-23 Seattle Children's Hospital Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP4034554A4 (en) 2019-09-23 2023-10-25 The Trustees of the University of Pennsylvania DESTRUCTION OF TUMOR TISSUE BY TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP)
BR112022005404A2 (pt) * 2019-09-23 2022-06-21 Univ Pennsylvania Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap)
US20220403041A1 (en) * 2019-11-15 2022-12-22 Genzyme Corporation Biparatopic cd73 antibodies
EP4061420A1 (en) * 2019-11-20 2022-09-28 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
US20220411497A1 (en) * 2019-12-17 2022-12-29 Phanes Therapeutics, Inc. Bispecific Antibodies with Alternatively Matched Interchain Cysteines and Uses Thereof
AU2020419293A1 (en) 2020-01-03 2022-07-28 Incyte Corporation CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
MX2022007575A (es) 2020-01-03 2022-09-23 Incyte Corp Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
WO2021202807A1 (en) * 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
EP4141033A4 (en) * 2020-04-22 2024-05-29 Akeso Biopharma, Inc. BISPECIFIC ANTI-CD73-ANTI-PD-1 ANTIBODY AND ITS USE
US20230159655A1 (en) * 2020-04-22 2023-05-25 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
AU2021264006A1 (en) * 2020-04-30 2022-12-01 Arch Oncology, Inc. Therapeutic sirpalpha antibodies
EP4197555A4 (en) * 2020-08-17 2025-03-12 Akeso Biopharma, Inc. ANTI-CD73 ANTIBODIES AND USE THEREOF
CN120590533A (zh) * 2020-10-23 2025-09-05 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN117264060A (zh) * 2020-11-09 2023-12-22 江苏中新医药有限公司 抗胞外-5’-核苷酸酶的抗体及其在制备肿瘤药物中的应用
WO2022122004A1 (zh) * 2020-12-11 2022-06-16 上海华奥泰生物药业股份有限公司 Cd73的抗原结合蛋白及其应用
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
EP4299589A4 (en) * 2021-02-24 2025-06-11 Novoprotein Scientififc Inc. HUMAN ANTI-CD73 ANTIBODY AND ITS USE
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
CA3229705A1 (en) * 2021-08-19 2023-02-23 Adicet Therapeutics, Inc. Methods for detection of membrane bound glypican-3
CN116265486A (zh) * 2021-12-17 2023-06-20 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
US12187806B2 (en) * 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116063467B (zh) * 2022-08-24 2025-10-14 浙江大学医学院附属第一医院 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用
WO2024243189A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Antigen binding proteins targeting pd-1
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN117567632B (zh) * 2023-11-27 2025-10-24 福州迈新生物技术开发有限公司 抗cd73蛋白单克隆抗体及其制备方法和应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US20180009899A1 (en) 2016-07-11 2018-01-11 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
JP2018501197A (ja) 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP2018502051A (ja) 2014-10-10 2018-01-25 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
WO2015164573A1 (en) 2014-04-25 2015-10-29 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
SI3221363T1 (sl) * 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CN109154611B (zh) 2015-12-09 2022-04-08 科尔沃斯制药股份有限公司 人源化抗cd73抗体
WO2017118613A1 (en) 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502051A (ja) 2014-10-10 2018-01-25 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断
JP2018501197A (ja) 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US20180009899A1 (en) 2016-07-11 2018-01-11 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies

Also Published As

Publication number Publication date
CN111867628A (zh) 2020-10-30
CN111867628B (zh) 2024-08-23
KR20250065424A (ko) 2025-05-12
WO2019173291A1 (en) 2019-09-12
IL276950A (en) 2020-10-29
BR112020016049A2 (pt) 2020-12-08
NZ766968A (en) 2024-12-20
ZA202004827B (en) 2023-06-28
MX2020009366A (es) 2020-10-14
AU2019231172B2 (en) 2023-08-24
KR102804816B1 (ko) 2025-05-09
EP3762030A4 (en) 2022-01-05
KR20200128542A (ko) 2020-11-13
JP2023162257A (ja) 2023-11-08
US11299550B2 (en) 2022-04-12
CN118955714A (zh) 2024-11-15
SG11202007199XA (en) 2020-09-29
AU2019231172A1 (en) 2020-09-03
JP2021516057A (ja) 2021-07-01
EP3762030A1 (en) 2021-01-13
US20200399389A1 (en) 2020-12-24
JP7636483B2 (ja) 2025-02-26
CA3090008A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
JP7334177B2 (ja) 抗ｃｄ７３抗体及びその使用
AU2019232762B2 (en) Anti-claudin 18.2 antibodies and uses thereof
US11214615B2 (en) Anti-TIM-3 antibodies and uses thereof
US12037391B2 (en) Anti-DLL3 antibodies and uses thereof
CN111050792B (zh) 抗lag-3抗体及其用途
KR102808710B1 (ko) 항-폴레이트 수용체 1 항체 및 이의 용도
WO2019173417A1 (en) Anti-tip-1 antibodies and uses thereof
HK40031477B (zh) 抗cd73抗体及其用途
EA043284B1 (ru) Антитела против cd73 и их применения
HK40031477A (en) Anti-cd73 antibodies and uses thereof
HK40033064B (en) Anti-folate receptor 1 antibodies and uses thereof
HK40033064A (en) Anti-folate receptor 1 antibodies and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230816

R150 Certificate of patent or registration of utility model

Ref document number: 7334177

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150